Cargando…

Metformin and Insulin Resistance: A Review of the Underlying Mechanisms behind Changes in GLUT4-Mediated Glucose Transport

Metformin is the most commonly used treatment to increase insulin sensitivity in insulin-resistant (IR) conditions such as diabetes, prediabetes, polycystic ovary syndrome, and obesity. There is a well-documented correlation between glucose transporter 4 (GLUT4) expression and the level of IR. There...

Descripción completa

Detalles Bibliográficos
Autores principales:	Herman, Rok, Kravos, Nika Aleksandra, Jensterle, Mojca, Janež, Andrej, Dolžan, Vita
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8836112/ https://www.ncbi.nlm.nih.gov/pubmed/35163187 http://dx.doi.org/10.3390/ijms23031264

Ejemplares similares

Effects of metformin withdrawal after long and short term treatment in PCOS: observational longitudinal study
por: Kravos, Nika Aleksandra, et al.
Publicado: (2021)

Long-term efficacy of metformin in overweight-obese PCOS: longitudinal follow-up of retrospective cohort
por: Jensterle, Mojca, et al.
Publicado: (2019)

SLC6A4 5HTTLPR Polymorphism Affects Insulin Secretion in Patients with Polycystic Ovary Syndrome
por: Šenk, Barbara, et al.
Publicado: (2018)

Short-term effectiveness of low dose liraglutide in combination with metformin versus high dose liraglutide alone in treatment of obese PCOS: randomized trial
por: Jensterle, Mojca, et al.
Publicado: (2017)

Insulin Metabolism in Polycystic Ovary Syndrome: Secretion, Signaling, and Clearance
por: Herman, Rok, et al.
Publicado: (2023)

Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin
por: Jensterle Sever, Mojca, et al.
Publicado: (2014)

Genetic Variability in Antioxidative and Inflammatory Pathways Modifies the Risk for PCOS and Influences Metabolic Profile of the Syndrome
por: Herman, Rok, et al.
Publicado: (2020)

Therapeutic Potential of Glucagon-like Peptide-1 Agonists in Polycystic Ovary Syndrome: From Current Clinical Evidence to Future Perspectives
por: Jensterle, Mojca, et al.
Publicado: (2022)

Assessment of Eating Disorders and Eating Behavior to Improve Treatment Outcomes in Women with Polycystic Ovary Syndrome
por: Kolnikaj, Tea Shehu, et al.
Publicado: (2022)

Metformin as an initial adjunct to low-dose liraglutide enhances the weight-decreasing potential of liraglutide in obese polycystic ovary syndrome: Randomized control study
por: JENSTERLE, MOJCA, et al.
Publicado: (2016)

Impact of COVID-19 Pandemic on Disease Control Status and Quality of Life of Patients with Acromegaly
por: Herman, Rok, et al.
Publicado: (2022)

Brown Adipose Tissue: A New Potential Target for Glucagon-like Peptide 1 Receptor Agonists in the Treatment of Obesity
por: Hropot, Tim, et al.
Publicado: (2023)

Prolactin in Polycystic Ovary Syndrome: Metabolic Effects and Therapeutic Prospects
por: Mastnak, Lara, et al.
Publicado: (2023)

An impaired glucagon-like peptide-1 response is associated with prediabetes in polycystic ovary syndrome with obesity
por: Ferjan, Simona, et al.
Publicado: (2019)

The Role of Genetic Factors and Kidney and Liver Function in Glycemic Control in Type 2 Diabetes Patients on Long-Term Metformin and Sulphonylurea Cotreatment
por: Klen, Jasna, et al.
Publicado: (2014)

Short term monotherapy with GLP-1 receptor agonist liraglutide or PDE 4 inhibitor roflumilast is superior to metformin in weight loss in obese PCOS women: a pilot randomized study
por: Jensterle, Mojca, et al.
Publicado: (2015)

Insulin Stimulated-Glucose Transporter Glut 4 Is Expressed in the Retina
por: Sánchez-Chávez, Gustavo, et al.
Publicado: (2012)

Case Report: Multiple prolactinomas in a young man with Kallmann syndrome and familial hypocalciuric hypercalcemia
por: Jensterle, Mojca, et al.
Publicado: (2023)

Glucagon-Like Peptide 1 and Taste Perception: From Molecular Mechanisms to Potential Clinical Implications
por: Jensterle, Mojca, et al.
Publicado: (2021)

SARS-CoV-2 Omicron symptoms and adverse effects of GLP-1 RA therapy
por: Jensterle, Mojca, et al.
Publicado: (2022)

Semaglutide in Obesity: Unmet Needs in Men
por: Jensterle, Mojca, et al.
Publicado: (2023)

Glycaemia in low-premixed insulin analogue type 2 diabetes patients in a real-world setting: are the CGM targets met?
por: Krajnc, Mitja, et al.
Publicado: (2023)

SUN-221 Effects of Liraglutide on Obesity-Associated Functional Hypogonadism in Men: A Randomized, Testosterone Replacement Treatment-Controlled Study
por: Jensterle Sever, Mojca, et al.
Publicado: (2019)

Effect of combined treatment with clozapine and metformin on fasting blood glucose, insulin level, and expression of the glucose transporter-2 (GLUT(2)) in Sprague-Dawley rats
por: Gao, Lan, et al.
Publicado: (2013)

The prevalence and characteristics of non-functioning and autonomous cortisol secreting adrenal incidentaloma after patients’ stratification by body mass index and age
por: Podbregar, Ana, et al.
Publicado: (2020)

Efficacy of GLP-1 RA Approved for Weight Management in Patients With or Without Diabetes: A Narrative Review
por: Jensterle, Mojca, et al.
Publicado: (2022)

An Insulin-Like Modular Basis for the Evolution of Glucose Transporters (GLUT) with Implications for Diabetes
por: Root-Bernstein, Robert
Publicado: (2007)

Development of Glucose Transporter (GLUT) Inhibitors
por: Reckzeh, Elena S., et al.
Publicado: (2019)

Expression of the glucose transporters GLUT1, GLUT3, GLUT4 and GLUT12 in human cancer cells
por: Barron, Carly, et al.
Publicado: (2012)

Distinct signals in the GLUT4 glucose transporter for internalization and for targeting to an insulin-responsive compartment
Publicado: (1995)

Expression of GLUT1 and GLUT3 Glucose Transporters in Endometrial and Breast Cancers
por: Krzeslak, Anna, et al.
Publicado: (2012)

Endocrine disorders after heart transplantation: national cohort study
por: Rakusa, Matej, et al.
Publicado: (2020)

Glucose transporters GLUT1, GLUT3, and GLUT4 have different effects on osteoblast proliferation and metabolism
por: Arponen, Milja, et al.
Publicado: (2022)

NLRP3 Inflammasome Polymorphism and Macrovascular Complications in Type 2 Diabetes Patients
por: Klen, Jasna, et al.
Publicado: (2015)

Action of Phytochemicals on Insulin Signaling Pathways Accelerating Glucose Transporter (GLUT4) Protein Translocation
por: Sayem, Abu Sadat Md, et al.
Publicado: (2018)

Regulation of GLUT4 and Insulin-Dependent Glucose Flux
por: Olson, Ann Louise
Publicado: (2012)

INDIVIDUALIZATION OF CUSTOM COMPOUNDED HORMONE THERAPY IN A PATIENT WITH CHEMOTHERAPY INDUCED PREMATURE OVARIAN INSUFFICIENCY AND IMPAIRED LIVER FUNCTION – CASE REPORT
por: Franić, Damir, et al.
Publicado: (2019)

Glucose Metabolism and Dynamics of Facilitative Glucose Transporters (GLUTs) under the Influence of Heat Stress in Dairy Cattle
por: Abbas, Zaheer, et al.
Publicado: (2020)

Osmotic Water Transport with Glucose in GLUT2 and SGLT
por: Naftalin, Richard J.
Publicado: (2008)

Placental expression of glucose transporters GLUT‐1, GLUT‐3, GLUT‐8 and GLUT‐12 in pregnancies complicated by gestational and type 1 diabetes mellitus
por: Stanirowski, Paweł Jan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ss7haukjn12t6lunk5757e6rak